EA201990540A1 - Лекарственные формы цистеамина и производных цистеамина - Google Patents

Лекарственные формы цистеамина и производных цистеамина

Info

Publication number
EA201990540A1
EA201990540A1 EA201990540A EA201990540A EA201990540A1 EA 201990540 A1 EA201990540 A1 EA 201990540A1 EA 201990540 A EA201990540 A EA 201990540A EA 201990540 A EA201990540 A EA 201990540A EA 201990540 A1 EA201990540 A1 EA 201990540A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cysteamine
derivatives
medicinal forms
medicinal
forms
Prior art date
Application number
EA201990540A
Other languages
English (en)
Inventor
Паоло Коломбо
Алессандра Росси
Грета Адорни
Марко Барчелли
Original Assignee
Рекордати Индустриа Чимика Е Фармасеутика Спа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рекордати Индустриа Чимика Е Фармасеутика Спа filed Critical Рекордати Индустриа Чимика Е Фармасеутика Спа
Publication of EA201990540A1 publication Critical patent/EA201990540A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Описана пероральная лекарственная форма цистеамина, состоящая из сухих чередующихся слоев микрочастиц липидной матрицы, пригодная для лечения цистиноза и нейродегенеративных расстройств.
EA201990540A 2016-10-11 2017-10-10 Лекарственные формы цистеамина и производных цистеамина EA201990540A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16193180.3A EP3308773A1 (en) 2016-10-11 2016-10-11 Formulations of cysteamine and cysteamine derivatives
PCT/EP2017/075801 WO2018069313A1 (en) 2016-10-11 2017-10-10 Formulations of cysteamine and cysteamine derivatives

Publications (1)

Publication Number Publication Date
EA201990540A1 true EA201990540A1 (ru) 2019-08-30

Family

ID=57130210

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201990540A EA201990540A1 (ru) 2016-10-11 2017-10-10 Лекарственные формы цистеамина и производных цистеамина

Country Status (13)

Country Link
US (1) US10813888B2 (ru)
EP (2) EP3308773A1 (ru)
JP (1) JP2019533668A (ru)
KR (1) KR102321156B1 (ru)
AU (1) AU2017341350B2 (ru)
BR (1) BR112019006049A2 (ru)
CA (1) CA3034554A1 (ru)
CO (1) CO2019003858A2 (ru)
EA (1) EA201990540A1 (ru)
IL (1) IL264898B2 (ru)
MX (1) MX2019003300A (ru)
UA (1) UA123838C2 (ru)
WO (1) WO2018069313A1 (ru)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80393C2 (ru) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтическая композиция, которая содержит ингибитор фдэ 4, диспергированный в матрице
WO2007002433A1 (en) 2005-06-22 2007-01-04 Plexxikon, Inc. Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors
PT2535044T (pt) 2006-01-27 2020-03-26 Univ California Cistamina e bitartarato de cisteamina revestidas entericamente
EP2172203A1 (en) 2008-09-17 2010-04-07 Giuliani S.P.A. Pharmaceutical composition for the treatment of gastrointestinal irritation disorders
WO2011031785A2 (en) * 2009-09-08 2011-03-17 Palm, Inc. Touchscreen with z-velocity enhancement
CN105451771B (zh) * 2013-03-15 2020-05-19 阿根塔创新有限公司 可咀嚼配制物
AR096628A1 (es) * 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
CN103652366B (zh) 2013-09-17 2017-07-07 杭州康德权饲料有限公司 一种稳定微囊包膜半胱胺盐酸盐及其制备方法
WO2016005994A2 (en) * 2014-07-06 2016-01-14 Gattefosse India Pvt. Ltd. Pharmaceutical composition comprising solid dispersion of bcs class ii drugs with gelucires

Also Published As

Publication number Publication date
JP2019533668A (ja) 2019-11-21
IL264898B1 (en) 2023-03-01
IL264898A (en) 2019-05-30
CO2019003858A2 (es) 2019-04-30
BR112019006049A2 (pt) 2019-06-25
EP3525761A1 (en) 2019-08-21
WO2018069313A1 (en) 2018-04-19
IL264898B2 (en) 2023-07-01
US20190216741A1 (en) 2019-07-18
EP3308773A1 (en) 2018-04-18
AU2017341350B2 (en) 2023-03-23
UA123838C2 (uk) 2021-06-09
MX2019003300A (es) 2019-05-22
KR20190057341A (ko) 2019-05-28
AU2017341350A1 (en) 2019-03-07
CA3034554A1 (en) 2018-04-19
US10813888B2 (en) 2020-10-27
KR102321156B1 (ko) 2021-11-03

Similar Documents

Publication Publication Date Title
CY1124729T1 (el) Φαρμακοτεχνικες μορφες του ενζαλουταμιδιου
MA52421A (fr) Composés pharmaceutiques
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
SV2017005601A (es) Formulaciones farmacéuticas que contienen tenofovir y emtricitabina
EA201692436A1 (ru) Медицинское применение
DOP2016000214A (es) Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma
EA201691582A1 (ru) Новые фармацевтические препараты
DK3727555T3 (da) Oral delivery of active drug substances
BR112017028140A2 (pt) formulações farmacêuticas
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
MA46867A (fr) Formulations pharmaceutiques
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
MA46621A (fr) Traitements combinés comprenant l&#39;administration d&#39;imidazopyrazinones
MA43800A (fr) Octréotide par voie orale pour le traitement de maladies
BR112016028518A2 (pt) composições farmacêuticas que compreendem dgla e uso do mesmo
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
CY1122348T1 (el) Μεθοδος για την θεραπευτικη αντιμετωπιση της ηπατικης εγκεφαλοπαθειας
MA54095A (fr) Formulations pharmaceutiques aqueuses
DK3634323T3 (da) Anordning til anvendelse som terapimiddel til terapeutisk behandling af camptocormi
EA201990540A1 (ru) Лекарственные формы цистеамина и производных цистеамина
AR110374A1 (es) Formas de dosificación de liberación modificada gastroretentivas para oprozomib y proceso para su fabricación
KR20180085033A (ko) 피부 질환 치료용 약학적 제형 및 이의 제조 방법
AR109209A1 (es) Composición farmacéutica para prevención o tratamiento de enfermedades neurodegenerativas
DOP2015000290A (es) Benzoxazoles sustituidos